Nathan T. James
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathan T. James has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Leena Choi
Department of Biostatistics Vanderbilt University Medical Center Nashville Tennessee USA
4 shared publications Brian Hachey
Department of Medicine Vanderbilt University Medical Center Nashville TN USA
2 shared publications- Cole Beck
Department of Biostatistics, Vanderbilt University Medical Center
2 shared publications Elizabeth McNeer
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
2 shared publicationsJacob M. Keaton
Department of Medicine Vanderbilt University Medical Center Nashville TN USA
2 shared publicationsMatthew D. Marshall
Department of Pharmaceutical Services Vanderbilt University Medical Center Nashville TN USA
2 shared publications
Latest Publications
- 28 January 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (6) , 2885-2898
Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens
Aims: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and electronic health records (EHRs) and explore the impact of patient's characteristics and pharmacogenetics on dexmedetomidine clearance.Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed‐effects modelling. Stage 1 developed a model without genotype variables; Stage 2 added pharmacogenetic effects.Results: Our final study population included 354 post‐cardiac surgery patients aged 0–22 years (median 16 mo). The data were best described with a 2‐compartment model with allometric scaling for weight and Hill maturation function for age. Population parameter estimates and 95% confidence intervals were 27.3 L/h (24.0–31.1 L/h) for total clearance, 161 L (139–187 L) for central compartment volume of distribution, 26.0 L/h (22.5–30.0 L/h) for intercompartmental clearance and 7903 L (5617–11 119 L) for peripheral compartment volume of distribution. The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5–42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99–7.08). Genotype was not statistically or clinically significant.Conclusion: Our study demonstrates the use of real‐world EHR data and remnant specimens to perform a population pharmacokinetic analysis and investigate covariate effects in a large paediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score.
- 28 January 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (6) , 2885-2898
Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens
Aims: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and electronic health records (EHRs) and explore the impact of patient's characteristics and pharmacogenetics on dexmedetomidine clearance.Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed‐effects modelling. Stage 1 developed a model without genotype variables; Stage 2 added pharmacogenetic effects.Results: Our final study population included 354 post‐cardiac surgery patients aged 0–22 years (median 16 mo). The data were best described with a 2‐compartment model with allometric scaling for weight and Hill maturation function for age. Population parameter estimates and 95% confidence intervals were 27.3 L/h (24.0–31.1 L/h) for total clearance, 161 L (139–187 L) for central compartment volume of distribution, 26.0 L/h (22.5–30.0 L/h) for intercompartmental clearance and 7903 L (5617–11 119 L) for peripheral compartment volume of distribution. The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5–42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99–7.08). Genotype was not statistically or clinically significant.Conclusion: Our study demonstrates the use of real‐world EHR data and remnant specimens to perform a population pharmacokinetic analysis and investigate covariate effects in a large paediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score.
- Open Access
Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real World Data from Electronic Health Records and Remnant Specimens
Aim: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and data from electronic health records (EHRs) and explore the impact of patient’s characteristics and pharmacogenetics on dexmedetomidine clearance. Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modeling. The first stage developed a model without genotype variables; the second stage added pharmacogenetic effects. Results: Our final study population included 354 post-cardiac surgery patients age 0 to 22 years (median 16 months). The final two-compartment model included allometric weight scaling and age maturation. Population parameter estimates and 95% confidence intervals were 27.3 L/hr (24.0 – 31.1 L/hr) for total clearance (CL), 161 L (139 – 187 L) for central compartment volume of distribution (V 1 ), 26.0 L/hr (22.5 – 30.0 L/hr) for intercompartmental clearance (Q), and 7903 L (5617 – 11119 L) for peripheral compartment volume of distribution (V 2 ). The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5 – 42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99 – 7.08). Genotype was not statistically or clinically significant. Conclusion: Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population PK analysis and investigate covariate effects in a large pediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score. What is already known about this subject: ∘ Previous dexmedetomidine pharmacokinetic (PK) studies in pediatric populations have limited sample size. ∘ Smaller studies present a challenge for identifying covariates that may impact individual PK profiles. What this study adds: ∘ We performed a dexmedetomidine population PK study with a large pediatric cohort using data obtained from electronic health records and remnant plasma specimens to enable increased sample size. ∘ xsDifferences in PK due to UGT1A4 or UGT2B10 variants or CYP2A6 risk score are not clinically impactful for this population.
Open AccessPopulation Pharmacokinetic Analysis of Dexmedetomidine in Children using Real World Data from Electronic Health Records and Remnant Specimens
Aim: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and data from electronic health records (EHRs) and explore the impact of patient’s characteristics and pharmacogenetics on dexmedetomidine clearance. Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modeling. The first stage developed a model without genotype variables; the second stage added pharmacogenetic effects. Results: Our final study population included 354 post-cardiac surgery patients age 0 to 22 years (median 16 months). The final two-compartment model included allometric weight scaling and age maturation. Population parameter estimates and 95% confidence intervals were 27.3 L/hr (24.0 – 31.1 L/hr) for total clearance (CL), 161 L (139 – 187 L) for central compartment volume of distribution (V 1 ), 26.0 L/hr (22.5 – 30.0 L/hr) for intercompartmental clearance (Q), and 7903 L (5617 – 11119 L) for peripheral compartment volume of distribution (V 2 ). The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5 – 42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99 – 7.08). Genotype was not statistically or clinically significant. Conclusion: Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population PK analysis and investigate covariate effects in a large pediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score. What is already known about this subject: ∘ Previous dexmedetomidine pharmacokinetic (PK) studies in pediatric populations have limited sample size. ∘ Smaller studies present a challenge for identifying covariates that may impact individual PK profiles. What this study adds: ∘ We performed a dexmedetomidine population PK study with a large pediatric cohort using data obtained from electronic health records and remnant plasma specimens to enable increased sample size. ∘ xsDifferences in PK due to UGT1A4 or UGT2B10 variants or CYP2A6 risk score are not clinically impactful for this population.
- 18 March 2021
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 28 (4) , 782-790
Building longitudinal medication dose data using medication information extracted from clinical notes in electronic health records
Objective: To develop an algorithm for building longitudinal medication dose datasets using information extracted from clinical notes in electronic health records (EHRs). Materials and Methods: We developed an algorithm that converts medication information extracted using natural language processing (NLP) into a usable format and builds longitudinal medication dose datasets. We evaluated the algorithm on 2 medications extracted from clinical notes of Vanderbilt’s EHR and externally validated the algorithm using clinical notes from the MIMIC-III clinical care database. Results: For the evaluation using Vanderbilt’s EHR data, the performance of our algorithm was excellent; F1-measures were ≥0.98 for both dose intake and daily dose. For the external validation using MIMIC-III, the algorithm achieved F1-measures ≥0.85 for dose intake and ≥0.82 for daily dose. Discussion: Our algorithm addresses the challenge of building longitudinal medication dose data using information extracted from clinical notes. Overall performance was excellent, but the algorithm can perform poorly when incorrect information is extracted by NLP systems. Although it performed reasonably well when applied to the external data source, its performance was worse due to differences in the way the drug information was written. The algorithm is implemented in the R package, “EHR,” and the extracted data from Vanderbilt’s EHRs along with the gold standards are provided so that users can reproduce the results and help improve the algorithm. Conclusion: Our algorithm for building longitudinal dose data provides a straightforward way to use EHR data for medication-based studies. The external validation results suggest its potential for applicability to other systems.
- 18 March 2021
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 28 (4) , 782-790
Building longitudinal medication dose data using medication information extracted from clinical notes in electronic health records
Objective: To develop an algorithm for building longitudinal medication dose datasets using information extracted from clinical notes in electronic health records (EHRs). Materials and Methods: We developed an algorithm that converts medication information extracted using natural language processing (NLP) into a usable format and builds longitudinal medication dose datasets. We evaluated the algorithm on 2 medications extracted from clinical notes of Vanderbilt’s EHR and externally validated the algorithm using clinical notes from the MIMIC-III clinical care database. Results: For the evaluation using Vanderbilt’s EHR data, the performance of our algorithm was excellent; F1-measures were ≥0.98 for both dose intake and daily dose. For the external validation using MIMIC-III, the algorithm achieved F1-measures ≥0.85 for dose intake and ≥0.82 for daily dose. Discussion: Our algorithm addresses the challenge of building longitudinal medication dose data using information extracted from clinical notes. Overall performance was excellent, but the algorithm can perform poorly when incorrect information is extracted by NLP systems. Although it performed reasonably well when applied to the external data source, its performance was worse due to differences in the way the drug information was written. The algorithm is implemented in the R package, “EHR,” and the extracted data from Vanderbilt’s EHRs along with the gold standards are provided so that users can reproduce the results and help improve the algorithm. Conclusion: Our algorithm for building longitudinal dose data provides a straightforward way to use EHR data for medication-based studies. The external validation results suggest its potential for applicability to other systems.
- 20 October 2017
- Published by The R Foundation
EHR: Electronic Health Record (EHR) Data Processing and Analysis Tool
- 20 October 2017
- Published by The R Foundation
EHR: Electronic Health Record (EHR) Data Processing and Analysis Tool